Regeneron Pharmaceuticals, Inc. Earnings

Regeneron Pharmaceuticals, Inc.’s revenue jumped 2.51% since last year same period to $3884.3Mn in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 3.46% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit fell -7.97% since last year same period to $844.6Mn in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -42.15% fall in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -10.22% since last year same period to 21.74% in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -44.09% fall in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 10.77 - a 11.38% jump from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 10.77.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -5.22% since last year same period to 11.44 in the Q4 2025. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -5.22% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Regeneron Pharmaceuticals, Inc. declared 0.88 dividend per share during the earnings announcement for Q4 2025.